聚乙二醇干扰素α-2a联合恩替卡韦治疗慢性乙型肝炎患者疗效及血清Pygo2和GP73水平变化

doi:10.3969/j.issn.1672-5069.2021.01.006

Abstract

Abstract: Objective The aim of this study was to analyze the serological and virological response to pegylated interferon α-2a (peg-IFN-α-2a) and entecavir combination in patients with chronic hepatitis B (CHB). Methods 77 patients with CHB were recruited in this study between February 2018 and February 2019, and divided randomly into control group (n=36) and observation group (n=41) . The patients in the control group were treated with entecavir, and those in the observation group were treated with peg-IFN-α-2a and entecavir combination for 24 weeks. Serum HBV DNA loads were detected by polymerase chain reaction, serum HBeAg and anti-HBe were detected by chemiluminescence method, and serum procollagen type III (PC III), laminin (LN), hyaluronic acid (HA), collagen type IV (IV-C), people end limb homologous protein 2 (Pygo2) and Golgi glycoprotein 73 (GP73) levels were detected by ELISA. Results At the end of 24 week treatment, serum HBV DNA negativity rates in the two groups were 100.0% vs. 100.0%, while serumHBeAg negativity rate in the observation group was 36.6%, significantly higher than that in the control group (19.4%, P<0.05), and serum HBeAg conversion to anti-HBe rate was 22.0%, significantly higher than that in the control group (8.3%, P<0.05); serum ALT level in the observation group was (32.3±13.5) U/L, significantly lower than that in the control group ; serum LN level in the observation group was (84.7±31.5) μg/L, significantly lower than that in the control group , Ⅳ-C level was (79.8±16.1) μg/L, significantly lower than that in the control group , PC-Ⅲ level was (94.5±21.2) μg/L, significantly lower than that in the control group , and serum HA levels was (107.1±25.2) μg/L, significantly lower than that in the control group ; serum Pygo2 level in the observation group was (50.8±5.9) μg/L, significantly lower than that in the control group , and serum GP73 level was (108.6±10.6) ng/mL, significantly lower than that in the control group .Conclusion The combination of entecavir and pegylated interferon α-2a for the treatment of patients with CHB could effectively improve serological and virological response, which might be related to the reduction of serum levels of Pygo2 and GP73 and relieve liver fibrosis.

Key words: Hepatitis B, Pegylated interferon α-2a, Entecavir, People end limb homologous protein 2, Golgi glycoprotein 73, Therapy

Zheng Zhiheng, Li Weiyun, Hui Zhenyu,et al. Serological and virological response topegylated interferon α-2a and entecavir combination in patients with chronic hepatitis B[J]. Journal of Practical Hepatology, 2021, 24(1): 19-22.

References

[1] Brancaccio G, Gaeta GB. Treatment of chronic hepatitis due to hepatitisb and hepatitis delta virus coinfection. Int J Antimicrob Agents, 2019, 54(6):697-701.
[2] Choi J, Kim HJ, Lee J, et al. Risk ofhepatocellular carcinoma in patients treated with entecavir vs tenofovir for chronic hepatitis b: a Korean nationwide cohort study. JAMA Oncol, 2019, 5(1):30-36.
[3] Wirth S , Zhang HF, Hardikar W, et al. Efficacy and safety of peginterferon alfa-2a (40kd) in children with chronic hepatitis B: the peg-b-active study. Hepatology, 2018, 68(5):1681-1694.
[4] 巴正武, 栗海龙. 多层螺旋CT门静脉成像评价肝硬化患者肝功能分级价值研究. 实用肝脏病杂志, 2019, 22(3):397-400.
[5] 王贵强, 王福生, 成军, 等. 慢性乙型肝炎防治指南(2015年版). 实用肝脏病杂志, 2016, 19(3):389-400.
[6] Hundie GB, Raj VS,Michael DG, et al. Molecular epidemiology and genetic diversity of hepatitis B virus in Ethiopia. J Med Virol, 2016, 88(6):1035-1043.
[7] Gschwantler M, Laferl H, Vogel W, et al. Efficacy of peginterferon plus ribavirin in patients receiving opioid substitution therapy: final results of the Austrian peghope study. Wien Klin Wochenschr, 2017, 130(1-2):1-8.
[8] Jindal A, Vyas AK, Kumar D, et al. Higher efficacy of pegylated interferon-α2b add-on therapy in hepatitisb envelope antigen-positive chronic hepatitis B patients on tenofovir monotherapy. J Hepatol, 2018, 48(6):451-458.
[9] 李卫, 李丽军, 李永华, 等. 回顾性分析聚乙二醇干扰素治疗HBeAg阳性慢性乙型肝炎患者抗病毒方案调整分析. 中华医院感染学杂志, 2017, 27(14):3192-3195.
[10] 王丽旻, 张鸿飞, 董漪, 等. α-干扰素治疗慢性乙型肝炎儿童对身高及体质量的影响. 中华传染病杂志, 2017, 35(1):11-14.
[11] Boglione L, Cariti G, Ghisetti V, et al. Extended duration of treatment with peginterferon alfa-2a in patients with chronic hepatitis B, HBeAg-negative and e genotype: a retrospective analysis. J Med Virol, 2018, 90(6):1047-1052.
[12] Hsu CW, Su WW, Lee CM, et al. Phase iv randomized clinical study: peginterferon alfa-2a with adefovir or entecavir pre-therapy for HBeAg-positive chronic hepatitis B. J Formos Med Assoc, 2018, 117(7):588-597.
[13] Lampertico P, Messinger D, Cornberg M, et al. A genotype-specific baseline score to predict response at 48 weeks post-treatment to peginterferon alfa-2a in patients with HBeAg-negative chronic hepatitis B. J Hepatol, 2016, 64(2):S599-S600.
[14] Ding Y, Lou JF, Hong C, et al. Tolerability, pharmacokinetics and antiviral activity of rhsa/ifnα2a for the treatment of chronic hepatitis B infection. Br J Clin Pharmacol, 2017, 83(5):1056-1071.
[15] Czerwionka-Szaflarska M, Chrobot A, Szaflarska-Szczepanik A. Studies of the effectiveness of interferon alpha treatment for chronic hepatitis C in children. Med Sci Monit, 2000, 6(5):964-970.
[16] Rizzo MD, Crawford RB, Henriquez JE, et al. HIV infected cannabis users have lower circulating cd16+monocytes and ifn-γ-inducible protein 10 levels compared with nonusing HIV patients. AIDS, 2018, 32(4):419-429.
[17] He LT, Ye GX, Zhou XY. Effect of switching from treatment with nucleos(t)ide analogs to pegylated interferon α-2a on virological and serological responses in chronic hepatitis B patients. World J Gastroenterol, 2016, 22(46): 10210-10218.
a) Huang Y, Li MH, Hou M, et al. Peginterferon alfa-2a for the treatment of chronic hepatitis C in the era of direct-acting antivirals. Hepatobiliary Pancreat Dis Int, 2017, 16(5):470-479.
[18] Martinot-Peignoux M, Lapalus M, Maylin S, et al. Baseline HBsAg and HBcrAg titres allow peginterferon-based 'precision medicine' in HBeAg-negative chronic hepatitis B patients. J Viral Hepatol, 2016, 23(11):905-911.
[19] Marcellin P, Sang HA, Ma X, et al. Combination of tenofovir disoproxil fumarate and peginterferon a-2a increases loss of hepatitis B surface antigen in patients with chronic hepatitis B. Gastroenterology, 2016, 150(1):134-144.

Serological and virological response topegylated interferon α-2a and entecavir combination in patients with chronic hepatitis B

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Zhou Xinmin, Ding Xiaopeng. Highlights of conventional supporting therapy for patients with primary liver cancer [J]. Journal of Practical Hepatology, 2021, 24(1): 4-6.
[2]	Liu Qi, Hao Jiqing. Immunotherapy of patients with hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2021, 24(1): 7-9.
[3]	Wu Dongqiu,Cui Lihua,Xiong Feng,et al. Diagnostic efficacy of serum IL-34 level and transient elastography in predicting liver fibrosis in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2021, 24(1): 23-26.
[4]	Lin Jinxiang, Yang Keli. Comparison of response toPEG-IFNα-2a or PEG-IFNα-2b in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2021, 24(1): 27-30.
[5]	Fan Bingdong, Zhang Guohua, Wang Jun. An observation of clinical efficacy of sofosbuvir/vipatavir and ribavirin combination in the treatment of patients with chronic hepatitis C [J]. Journal of Practical Hepatology, 2021, 24(1): 31-34.
[6]	Yang Xiaodong,Jia Ting,Zhang Xiuling, et al. Short-term efficacy of danorevir and peginterferon-α in the treatment of patients with genotype 3 infected chronic hepatitis C [J]. Journal of Practical Hepatology, 2021, 24(1): 35-38.
[7]	Wei Xiuqin, Yan Xiaoxia, Shi Guorong, et al. Short-termefficacy of atorvastatin and tiopronin combination in the treatment of patients with nonalcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2021, 24(1): 47-50.
[8]	Li Zhao, Huang Zansong , Li Fan. Application of fenofibrate and bicyclol combination in treatment of patients with non-alcoholic fatty liver diseases and changes of hepatic PPARγ₂ [J]. Journal of Practical Hepatology, 2021, 24(1): 59-62.
[9]	Chen Jinyu, Guo Xiaoxia, Zhong Xiaoni. Efficacy of bifidobacterium triple viable capsuleand metformin in treatment of patients with nonalcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2021, 24(1): 63-66.
[10]	Chen Yanping, Huang Shaoqiang,Deng Xin ,et al. Short-term efficacy of tiopronin and polyene phosphatidylcholine combination in treatment of patients with alcoholic liver disease [J]. Journal of Practical Hepatology, 2021, 24(1): 67-70.
[11]	Cai Yu, Wang Mengchun, Qiu Xinping, et al. Improvement of liver function and subsiding jaundice by compound glycyrrhizin and adenosylmethionine succinate in the treatment of patients with alcoholic hepatitis [J]. Journal of Practical Hepatology, 2021, 24(1): 71-74.
[12]	Wu Chang,Tian Yuan,Liu Hongyan. Short-term efficacy of live clostridium butyricum in assisting tiopronin and metadoxine in treatment of patients with alcoholic liver disease [J]. Journal of Practical Hepatology, 2021, 24(1): 75-78.
[13]	Li Qingling, He Shuguang, Yi Xiaoming, et al. Changes of peripheral blood lymphocyte PD-1 and PD-L1 expression in patients with autoimmune hepatitis receiving tripterygium wilfordii polyglycosides and magnesium iso-glycyrrhizate [J]. Journal of Practical Hepatology, 2021, 24(1): 79-82.
[14]	Zeng Jiao, Guo Guihai. Efficacy and safety of polyethylene glycol and lactulose in the treatment of patients with hepatic encephalopathy:a Meta-analysis [J]. Journal of Practical Hepatology, 2021, 24(1): 99-102.
[15]	Fan Jing, Xu Jing, Yuan Xue. Combination of rifaximin and lactulose improves clinical efficacy and mortality in hepatitis B cirrhotic patients with hepatic encephalopathy [J]. Journal of Practical Hepatology, 2021, 24(1): 103-106.